In effect, the expression of heteromers (HER2-CB2R) has been correlated with a poor prognosis, while their disruption promotes an antitumor response suggesting these heteromers could be used as therapeutic targets and prognostic tools in HER2-positive breast cancer [18]. This evidence concerns the gene ERBB2 and breast carcinoma.